Shares of cardiology instruments systems manufacturer Stereotaxis, Inc. (Nasdaq: STXS) are sagging despite news the St. Louis, Mo.-based company has developed an innovative new interface.

“Odyssey” is a new product that consolidates multiple information sources and screens within an electrophysiology interventional lab into a single visual display, Stereotaxis said before the opening bell.

For access to the full article, you must be a registered member - it's FREE.